Loading market dashboard
Mirum Pharmaceuticals, Inc.
MIRMHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals NASDAQ: MIRM executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering.
Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–$680M, reflecting strong visibility and momentum, especially from LIVMARLI and bile acid products. The BlueJay acquisition and late-stage programs in HDV, PSC, and FOP create a catalyst-rich period, supporting the premium valuation versus sector peers.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.3 per share a year ago.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main goal of a mid-stage study by reducing severe itching or pruritus in patients with a type of rare liver disease.
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) shares are up on Monday following the announcement that the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational treatment for cholestatic pruritus in patients with primary sclerosing cholangitis.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with PSC on May 4, 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
Vertex Pharmaceuticals has shown steady financial growth. Mirum Pharmaceuticals is getting closer to being profitable.
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals already markets three therapies. The company plans to report four pivotal readouts from clinical studies over the next 18 months.
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals (NASDAQ: MIRM).
SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,710 shares of the company's stock, valued at approximately $1,478,000. A number of other hedge funds and other institutional investors
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has assigned a strong buy rating
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 40,985 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating
